Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2001, Pages 691-695

  Azekawa, Takaharu ^a   Ohashi, Shizuko ^a   Itami, Akira ^a  

^a Shioiri Mental Clinic   (Japan)

Author keywords

Aripiprazole; Effectiveness; Retrospective study; Schizophrenia; Second generation antipsychotics; Treatment continuation

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERIN; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE;

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MENTAL HOSPITAL; OUTPATIENT; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 84856147767     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s26672     Document Type: Article

References (15)

1. Leucht S, Corves C, Arbter D, et al. Second-generation versus firstgeneration antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
2. Gentile S. A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole. Neuropsychiatr Dis Treat. 2009;5:117-125.
3. Hogarty GE, Schooler NR, Baker RW. Efficacy versus effectiveness. Psychiatr Serv. 1997;48:1107.
4. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
5. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: A CATIE study. Am J Psychiatry. 2007;164:415-427.
6. Coley KC, Fabian TJ, Kim E, et al. Predictors of aripiprazole treatment continuation in hospitalized patients. J Clin Psychiatry. 2008;69:1393-1397.
7. Gorwood P. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol. 2006;16:5156-5162.
8. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-389.
9. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137-140.
10. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of ariprazole predicts clinical efficacy and a favorable side-effect profile. J Psychopharmacol. 2004;18:375-383.
11. Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25:646-666.
12. Bergman F, Zacher A, Nass A, et al. Psychosocial functioning in patients with schizophrenia treated with aripiprazole-an office-based real-world setting. Results from the German post-marketing surveillance study. Pharmacopsychiatry. 2009;42:101-108.
13. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res. 2003;61:123-136.
14. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
15. Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patient with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res. 2006;84:77-89.